Drug intelligence / Profile preview

Olopatadine Evolute

Development stage: Unknown
Lead developer: Mati Therapeutics
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Ophthalmic

Overview

Olopatadine Evolute is a sustained-release ocular drug delivery system developed by Mati Therapeutics for the treatment of ocular allergies, specifically allergic conjunctivitis. It utilizes the proprietary Evolute Punctal Plug Delivery System (PPDS), which consists of a non-biodegradable silicone punctal plug containing a drug-eluting core. Once inserted into the punctum (tear duct), the device provides controlled, preservative-free release of olopatadine into the tear film over an extended period, typically several weeks. Olopatadine acts as a selective histamine H1 receptor antagonist and mast cell stabilizer, inhibiting the release of inflammatory mediators. This delivery method is designed to improve patient compliance and therapeutic consistency compared to traditional topical eye drops by providing a continuous dose of medication without the need for frequent administration.

Brand names: Evolute
Other names: Olopatadine PPDSOlopatadine Punctal PlugOlopatadine Evolute®

Targets

S100A1 (S100 calcium-binding protein A1)S100A12 (S100 calcium-binding protein A12)HRH1 (Histamine H1 Receptor)S100B (S100 Calcium-Binding Protein B)S100A13 (S100 calcium-binding protein A13)HRH2 (Histamine H2 Receptor)S100A2 (S100 calcium-binding protein A2)HRH3 (Histamine Receptor H3)

Beyond the preview

Go deeper on Olopatadine Evolute.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olopatadine Evolute.

Explore the full profile